How long should first-line chemotherapy continue?

被引:7
作者
Bertelsen, K [1 ]
Grenman, S
Rustin, GJS
机构
[1] Odense Univ Hosp, Dept Oncol, DK-5000 Odense C, Denmark
[2] Turku Univ, Cent Hosp, Dept Obstet & Gynaecol, Turku, Finland
[3] Mt Vernon Hosp, Dept Med Oncol, Northwood HA6 2RN, Middx, England
关键词
advanced ovarian cancer; chemotherapy; duration; treatment;
D O I
10.1023/A:1008399132535
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Documentation for the optimal duration of first-line chemotherapy in advanced ovarian cancer is limited. Three randomised trials have compared 5-6 cycles with 8, 10 and 12 cycles respectively. None of the studies showed benefit of chemotherapy beyond 6 cycles. At the moment the standard number of cycles therefore must be 6 cycles. However, these data are based on platinum poly-chemotherapy regimens without taxanes. It may be that the optimal number of cycles is different when using taxanes regimens. It is not possible to tell from the literature if there is a relationship between the number of cycles and response or between the cumulative dose and response. At the moment no trial has shown any benefit of high-dose intensity chemotherapy administered over a short time compared with standard dose chemotherapy administered over a longer period.
引用
收藏
页码:17 / 20
页数:4
相关论文
共 14 条
[11]  
*NIH, 1994, GYNECOL ONCOL, V55, P4
[12]  
SORBE B, 1996, P AN M AM SOC CLIN, V15, P287
[13]   Doxorubicin-melphalan with and without cisplatin in advanced ovarian cancer - Ten-year survival results from a prospective randomized study by the Swedish Cooperative Ovarian Cancer Study Group [J].
Trope, C ;
Andersson, H ;
Bjorkholm, E ;
Frankendal, B ;
Himmelman, A ;
Hogberg, T ;
Horvath, G ;
Petterson, B ;
Persson, H ;
Ryberg, M ;
Simonsen, E ;
Sorbe, B ;
Stendahl, U ;
Wesholm, B .
ACTA ONCOLOGICA, 1996, 35 :109-118
[14]   THE EFFECT OF DEBULKING SURGERY AFTER INDUCTION CHEMOTHERAPY ON THE PROGNOSIS IN ADVANCED EPITHELIAL OVARIAN-CANCER [J].
VANDERBURG, MEL ;
VANLENT, M ;
BUYSE, M ;
KOBIERSKA, A ;
COLOMBO, N ;
FAVALLI, G ;
LACAVE, AJ ;
NARDI, M ;
RENARD, J ;
PECORELLI, S .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (10) :629-634